Objective: To update the follow-up of the Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis. Patients and methods: Data for survival and kidney function were prospectively collected during a 10-year period for the 90 patients randomised in the ELNT, except in 6 lost to follow-up. Results: Death, sustained doubling of serum creatinine and end-stage renal disease rates did not differ between the LD and HD group (5/44 (11%) vs 2/46 (4%), 6/44 (14%) vs 5/46 (11%) and 2/44 (5%) vs 4/46 (9%), respectively) nor did mean serum creatinine, 24 h proteinuria and damage score at last follow-up. Most patients in both groups were still treated with glucocorticoids, other immunosuppressant agents and blood pressure lowering drugs. After 10 years of follow-up, the positive predictive value for a good outcome of an early drop in proteinuria in response to initial immunosuppressive therapy was confirmed. Conclusion: The data confirm that a LD IVCY regimen followed by AZA - the "Euro-Lupus regimen" - achieves good clinical results in the very long term

Houssiau, F., Vasconcelos, C., D'Cruz, D., Sebastiani, G., De Ramon Garrido, E., Danieli, M., et al. (2010). The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. ANNALS OF THE RHEUMATIC DISEASES, 69(1), 61-64 [10.1136/ard.2008.102533].

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

SINICO, RENATO ALBERTO;
2010

Abstract

Objective: To update the follow-up of the Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis. Patients and methods: Data for survival and kidney function were prospectively collected during a 10-year period for the 90 patients randomised in the ELNT, except in 6 lost to follow-up. Results: Death, sustained doubling of serum creatinine and end-stage renal disease rates did not differ between the LD and HD group (5/44 (11%) vs 2/46 (4%), 6/44 (14%) vs 5/46 (11%) and 2/44 (5%) vs 4/46 (9%), respectively) nor did mean serum creatinine, 24 h proteinuria and damage score at last follow-up. Most patients in both groups were still treated with glucocorticoids, other immunosuppressant agents and blood pressure lowering drugs. After 10 years of follow-up, the positive predictive value for a good outcome of an early drop in proteinuria in response to initial immunosuppressive therapy was confirmed. Conclusion: The data confirm that a LD IVCY regimen followed by AZA - the "Euro-Lupus regimen" - achieves good clinical results in the very long term
Articolo in rivista - Articolo scientifico
Adolescent; Adult; Azathioprine; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epidemiologic Methods; Female; Humans; Immunosuppressive Agents; Injections, Intravenous; Kidney Function Tests; Lupus Nephritis; Male; Middle Aged; Proteinuria; Treatment Outcome; Young Adult; Rheumatology; Immunology; Biochemistry, Genetics and Molecular Biology (all); Immunology and Allergy
English
61
64
4
Houssiau, F., Vasconcelos, C., D'Cruz, D., Sebastiani, G., De Ramon Garrido, E., Danieli, M., et al. (2010). The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. ANNALS OF THE RHEUMATIC DISEASES, 69(1), 61-64 [10.1136/ard.2008.102533].
Houssiau, F; Vasconcelos, C; D'Cruz, D; Sebastiani, G; De Ramon Garrido, E; Danieli, M; Abramovicz, D; Blockmans, D; Cauli, A; Direskeneli, H; Galeazzi, M; Gül, A; Levy, Y; Petera, P; Popovic, R; Petrovic, R; Sinico, R; Cattaneo, R; Font, J; Depresseux, G; Cosyns, J; Cervera, R
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/139370
Citazioni
  • Scopus 366
  • ???jsp.display-item.citation.isi??? 322
Social impact